Drug Trial Radar · NCT07394452
Single Ascending Dose Study(SAD),Multiple Ascending Dose Study(MAD) , High-fat Diet Study (FE) of TJ0113 Capsules in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
130
Actual
Start
Aug 4, 2023
Primary completion
Feb 5, 2024
Study completion Apr 3, 2024
Sponsor
- Lead sponsor
- Hangzhou PhecdaMed Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study included three clinical studies, namely a single ascending dose (SAD) study, a multiple ascending dose (MAD) study, and a high-fat diet food effect (FE) study.
Conditions
- Healthy Subjects
Interventions
TJ0113 CapsulesDrug
Participants will receive oral administration of TJ0113.
PlaceboOther
Participants will receive oral administration of Placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse event (TEAE) incidence of TJ0113 capsules after single oral administration in SAD studyTime frame: Within 12 days after the last administration
- Treatment-emergent adverse event (TEAE) incidence of TJ0113 capsules after multiple oral administration in MAD studyTime frame: Within 12 days after the last administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhejiang Xiaoshan hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.